A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.

Key facts

Study ID

NCT00567203

Run by

Pfizer

People needed

36

Starts

2007-11-01

Expected to finish

2008-05-01

Last updated by the study team

2008-10-02

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia
• In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months
• Stable symptoms of schizophrenia for at least 3 months.

You may not qualify if…

• Subjects with a psychiatric disorder other than schizophrenia
• Substance dependence or abuse
• Women who have child bearing potential.

Where it is running

• Pfizer Investigational Site — Glendale, California, United States
• Pfizer Investigational Site — Willingboro, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.